AVITA Medical (ASX:AVH) Forward Rate of Return (Yacktman) %: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:AVH AVITA Medical Inc ASX:AVH
53 GF Score
Price A$2.71
GF Value A$2.27
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is AVITA Medical Forward Rate of Return (Yacktman) %?

AVITA Medical ASX:AVH +23.18% 53 Forward Rate of Return (Yacktman) % is 0.00% as of Jun. 2026. GuruFocus rates ASX:AVH with a GF Score™ of 53/100 and a GF Value™ of A$2.27 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 378 Medical Devices & Instruments companies, AVITA Medical ranks worse than 264550% on this metric.

Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. AVITA Medical's forward rate of return for was 0.00%.

The historical rank and industry rank for AVITA Medical's Forward Rate of Return (Yacktman) % or its related term are showing as below:

During the past 13 years, AVITA Medical's highest Forward Rate of Return was -2.15. The lowest was -12.52. And the median was -5.42.

ASX:AVH's Forward Rate of Return (Yacktman) % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 8.17
* Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.

Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


AVITA Medical  (ASX:AVH) Forward Rate of Return (Yacktman) % Explanation

Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.


Be Aware

In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.


AVITA Medical Forward Rate of Return (Yacktman) % Related Terms


AVITA Medical Forward Rate of Return (Yacktman) % Historical Data

* Premium members only.

The historical data trend for AVITA Medical's Forward Rate of Return (Yacktman) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AVITA Medical Forward Rate of Return (Yacktman) % Chart

AVITA Medical Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Dec22 Dec23 Dec24 Dec25
Forward Rate of Return (Yacktman) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

AVITA Medical Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Forward Rate of Return (Yacktman) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ASX:AVH vs OWLT, CVRX, STIM: Forward Rate of Return (Yacktman) % Comparison

For the Medical Devices subindustry, AVITA Medical's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AVITA Medical Forward Rate of Return (Yacktman) % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AVITA Medical's Forward Rate of Return (Yacktman) % distribution charts can be found below:

* The bar in red indicates where AVITA Medical's Forward Rate of Return (Yacktman) % falls into.


ASX:AVH
53GF Score
AVITA Medical Inc ASX:AVH
Forward Rate of Return (Yacktman) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AVITA Medical Forward Rate of Return (Yacktman) % Calculation

Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

AVITA Medical's Forward Rate of Return of Jun. 2026 is

Forward Rate of Return=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0/1.2+0
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Forward Rate of Return (Yacktman) % of 0.00% mean?
AVITA Medical (ASX:AVH) has a Forward Rate of Return (Yacktman) % of 0.00% as of Jun. 2026. Yacktman's forward rate of return equals the sum of normalized free-cash-flow yield plus earnings growth. View historical data on AVITA Medical and its competitors. According to the industry distribution chart, AVITA Medical ranks #999999 out of 378 companies in the Medical Devices & Instruments industry.
Is AVITA Medical's Forward Rate of Return (Yacktman) % too high?
AVITA Medical's current Forward Rate of Return (Yacktman) % is 0.00%. Based on the distribution chart, AVITA Medical ranks #999999 out of 378 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, AVITA Medical has a GF Score™ of 53/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AVITA Medical's Forward Rate of Return (Yacktman) % compare to OWLT and CVRX?
According to the Medical Devices & Instruments industry distribution chart, AVITA Medical ranks #999999 out of 378 companies for Forward Rate of Return (Yacktman) %. This places AVITA Medical in the lower half of its industry. The industry median Forward Rate of Return (Yacktman) % is 8.17. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Rate of Return (Yacktman) % for a Medical Devices & Instruments company?
The median Forward Rate of Return (Yacktman) % among Medical Devices & Instruments companies is 8.17, based on 378 companies in the industry. Companies in the top quartile (top 25%) have a Forward Rate of Return (Yacktman) % significantly above this median, while those in the bottom quartile fall well below. However, Forward Rate of Return (Yacktman) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Rate of Return (Yacktman) % mean?
A high Forward Rate of Return (Yacktman) % can signal that a stock is expensive relative to its fundamentals. Yacktman's forward rate of return equals the sum of normalized free-cash-flow yield plus earnings growth. View historical data on AVITA Medical and its competitors. For the Medical Devices & Instruments industry, the median Forward Rate of Return (Yacktman) % is 8.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AVITA Medical's current Forward Rate of Return (Yacktman) % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AVITA Medical stock overvalued right now?
Based on GuruFocus' analysis, AVITA Medical (ASX:AVH) is currently considered Modestly Overvalued. The stock's GF Value™ is A$2.27, compared to a current price of A$2.71 — trading 19.4% above its estimated fair value. The current Forward Rate of Return (Yacktman) % is 0.00%. AVITA Medical's overall GF Score™ is 53/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Rate of Return (Yacktman) % calculated?
Forward Rate of Return (Yacktman) % is calculated from a company's financial statements. For AVITA Medical (ASX:AVH), the current Forward Rate of Return (Yacktman) % is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AVITA Medical (ASX:AVH) Overvalued in 2026?

Based on GuruFocus' analysis, AVITA Medical stock appears to be overvalued. The current stock price of A$2.71 is trading 19.4% above its estimated GF Value™ of A$2.27. GuruFocus considers AVITA Medical to be Modestly Overvalued.

Key valuation signals for ASX:AVH:

  • Forward Rate of Return (Yacktman) %: 0.00%
  • GF Value™: A$2.27 vs. price of A$2.71 (19.4% above fair value)
  • GF Score™: 53/100 with 8 warning signs

No single metric tells the full story. See the ASX:AVH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AVITA Medical Business Description

Address 28159 Avenue Stanford, Suite 220, Valencia, Santa Clarita, CA, USA, 91355
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
53GF Score

Get the complete analysis for ASX:AVH

Forward Rate of Return (Yacktman) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.71
Price
A$2.27
GF Value